Frans Erdkamp

7.3k citations

82 papers · 3.7k indexed · 2 hit papers · h-index 26

Oncology top 0.5%
- Cancer Treatment and Pharmacology 30
- HER2/EGFR in Cancer Research 16
- Colorectal Cancer Treatments and Studies 10
- Cancer survivorship and care 7
Hepatology top 2%
Pulmonary and Respiratory Medicine top 2%
- Advanced Breast Cancer Therapies 19
Cancer Research top 5%
- Breast Cancer Treatment Studies 20
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment 7
Genetics
- Estrogen and related hormone effects 7

Co-authors: Miriam Koopman Cornelis J.A. Punt C. J. Rodenburg Ninja Antonini Linda Mol Otilia Dalesio Harm Sinnige Annemieke Cats
Cited by: Oncology Hepatology Pulmonary and Respiratory Medicine
Journals: Annals of Oncology (15 papers)Journal of Clinical Oncology (9 papers)Breast Cancer Research and Treatment (9 papers)
Partner nations: Netherlands United States United Kingdom

In The Last Decade

Frans Erdkamp

80 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Frans Erdkamp

Since Specialization

Citations

This map shows the geographic impact of Frans Erdkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frans Erdkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frans Erdkamp more than expected).

Fields of papers citing papers by Frans Erdkamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frans Erdkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frans Erdkamp. The network helps show where Frans Erdkamp may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frans Erdkamp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frans Erdkamp Line = papers co-authored together Frans Erdkamp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03) Annals of Oncology ·Huang Zhongcai,Stephen B. H. Kent,Inge R. Konings,K. Seki,Vincent van der Noort,E. van den Pol,Felicia Citra Wibawa,Chao Zhang,K. S. Sarin,Frans Erdkamp,Danny Houtsma,Hendrika M. Oosterkamp,Peter Krapp,H Hubbard1,J. Tol,Annette A. van Zweeden,A. Elise van Leeuwen‐Stok,Gabe S. Sonke,Agnes Jager,Hedwig M. Blommestein	2024	1
2	The prognostic impact of BMI in patients with HR+/HER2− advanced breast cancer: a study of the SONABRE registry Breast Cancer Research and Treatment ·A. Zijlmans,Р С Игембаева,Ingeborg J. H. Vriens,Adam Cassis,Sanne Engelen,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,William Fawley,Manon J. Pepels,Maidan Fahmi,Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,Bakary Coulibaly,Sandra M. E. Geurts,Vivianne C. G. Tjan‐Heijnen	2023	4
3	Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry The Lancet Regional Health - Europe ·Adam Cassis,Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,William Fawley,Manon J. Pepels,Maidan Fahmi,Natascha A. J. B. Peters,Jolien Tol,Joan B. Heijns,Agnès J. van de Wouw,Earl G. Lee,Hirohito SUZUKI,Vivianne C. G. Tjan‐Heijnen	2023	15
4	The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer JNCI Cancer Spectrum ·A. Zijlmans,Sandra M. E. Geurts,Irene E.G. van Hellemond,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Marjolein L. Smidt,Ingeborg J. H. Vriens,Vivianne C. G. Tjan‐Heijnen	2023	4
5	Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial EClinicalMedicine ·Vivianne C. G. Tjan‐Heijnen,A. Zijlmans,Sandra M. E. Geurts,Ingeborg J. H. Vriens,Astrid C P Swinkels,Carolien H. Smorenburg,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,W Roos,Sabine C. Linn,Alexander L.T. Imholz	2023	11
6	Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry Clinical Breast Cancer ·Claude Lafleur,Sandra M. E. Geurts,Anna K. McVittie,Adam Cassis,Frans Erdkamp,Joan B. Heijns,Jolien Tol,Birgit E. P. J. Vriens,William Fawley,M. Wouter Dercksen,Manon J. Pepels,Natascha A. J. B. Peters,Maidan Fahmi,Agnès J. van de Wouw,Don Lambert,Hirohito SUZUKI,Vivianne C. G. Tjan‐Heijnen	2023	1
7	The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry International Journal of Cancer ·Adam Cassis,Sandra M. E. Geurts,Frans Erdkamp,M. Wouter Dercksen,Birgit E. P. J. Vriens,William Fawley,Manon J. Pepels,Maidan Fahmi,Bakary Coulibaly,Maaike de Boer,Vivianne C. G. Tjan‐Heijnen	2021	10
8	Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer Samaha,Frans Erdkamp,Marta López‐Yurda,А.Г. Пономарев,Jeany M. Rademaker-Lakhai,A.H. Honkoop,Osada Fujiko,Vivianne C. G. Tjan‐Heijnen,Mandlik RM	2020	1
9	Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer Annals of Oncology ·Samaha,최고로,Jan J.V. Busschbach,А.Г. Пономарев,Jeany M. Rademaker-Lakhai,Frans Erdkamp,Vivianne C. G. Tjan‐Heijnen,Mandlik RM	2019	0
10	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study International Journal of Cancer ·Irene E.G. van Hellemond,Carolien H. Smorenburg,Petronella G.M. Peer,Astrid C P Swinkels,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	2019	11
11	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure International Journal of Cancer ·Irene E.G. van Hellemond,Ingeborg J. H. Vriens,Petronella G.M. Peer,Astrid C P Swinkels,Carolien H. Smorenburg,Caroline Seynaeve,Maurice J.C. van der Sangen,Judith R. Kroep,Hiltje de Graaf,Aafke H. Honkoop,Frans Erdkamp,Franchette W.P.J. van den Berkmortel,Maaike de Boer,W Roos,Sabine C. Linn,Alexander L.T. Imholz,Vivianne C. G. Tjan‐Heijnen	2018	7
12	Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study BMJ Open ·Anne M. May,A. Nururrochman Hidayatulloh,Miranda J. Velthuis,Elsken van der Wall,Charlotte N. Steins Bisschop,Maartje Los,Frans Erdkamp,Haiko J. Bloemendal,Marnix A.J. de Roos,Marlies Verhaar,Daan ten Bokkel Huinink,Petra H.M. Peeters,G. Ardine de Wit	2017	43
13	Efficacy of two times four versus continuous eight cycles of paclitaxel/bevacizumab as first-line chemotherapy in metastatic breast cancer: The Stop&Go study of the Dutch Breast Cancer Research Group (BOOG) Annals of Oncology ·Samaha,Monique E.M.M. Bos,厚生省環境衛生局水道課,Hulan Yawen,Marta López‐Yurda,A.H. Honkoop,H. de Graaf,Barbara J. Krueckel,Roarke R. Cullenbine,نعمت کریمی,Vivianne C. G. Tjan‐Heijnen,Frans Erdkamp	2017	1
14	Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study Annals of Oncology ·Ahdha Jangga Buwana,Sjoerd G. Elias,Harm van Tinteren,Miangela M. Laclé,Stefan M. Willems,G.J.A. Offerhaus,Wendy W.J. de Leng,E Strengman,Albert J. ten Tije,G.J. Creemers,杨清华,Felix E. de Jongh,Frans Erdkamp,Bea C. Tanis,Cornelis J.A. Punt,Miriam Koopman	2017	56
15	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial Breast Cancer Research and Treatment ·Gabe S. Sonke,Lowell L. Hart,Mario Campone,Frans Erdkamp,Wolfgang Janni,Sunil Verma,Cristian Villanueva,Erik Jakobsen,Emilio Alba,Erik Wist,Anne Favret,Thomas Bachelot,Roberto Hegg,Paul Wheatley‐Price,Farida Souami,Santosh Sutradhar,Michelle C. Miller,Caroline Germa,Howard A. Burris	2017	61
16	Impact of sarcopenia on dose limiting toxicities in metastatic colorectal cancer patients (mCRC pts) receiving palliative systemic treatment Annals of Oncology ·Sophie A. Kurk,Petra H.M. Peeters,Rebecca K. Stellato,Bram Dorresteijn,Marion Jourdan,G.J. Creemers,Frans Erdkamp,Maya Alcántara,Mansudjon Murodjon Abdurakhmonov,H. Bokal,Sandra A. Radema,Lieke H. J. Simkens,Bea C. Tanis,Manuel L. R. Tjin‐A‐Ton,杨清华,Cornelis J.A. Punt,Miriam Koopman,Anne M. May	2017	3
17	[The electronic health record: computerised provider order entry and the electronic instruction document as new functionalities]. PubMed ·Joep P. M. Derikx,Frans Erdkamp,A. G. M. Hoofwijk	2013	2
18	Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice Supportive Care in Cancer ·Krzysztof Krzemieniecki,P. Sevelda,Frans Erdkamp,Martin Šmakal,Matthias Schwenkglenks,Raúl Barrantes Urbina,Andreas Trojan,Zsolt Szabó,Наталія Дзісь,Johanna Mäenpää	2013	25
19	Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study Annals of Oncology ·Miriam Koopman,Ninja Antonini,J. Douma,J. Wals,A.H. Honkoop,Frans Erdkamp,Robert S. de Jong,C. J. Rodenburg,Gerard Vreugdenhil,C. P. Lee,Cornelis J.A. Punt	2006	32
20	Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Annals of Oncology ·Stephen Chan,N. Davidson,Elona Juozaitytė,Frans Erdkamp,A Płużańska,N. Azarnia,Abderaouf BenAbderrahman	2004	114

About Frans Erdkamp

Frans Erdkamp is a scholar working on Medical Terminology, Oncology and Cancer Research, having authored 82 papers that have together received 3.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (20 papers), Advanced Breast Cancer Therapies (19 papers), HER2/EGFR in Cancer Research (16 papers), Colorectal Cancer Treatments and Studies (10 papers), Estrogen and related hormone effects (7 papers), Cancer survivorship and care (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). The work is most often cited by research in Oncology (2.7k citations), Hepatology (465 citations) and Pulmonary and Respiratory Medicine (1.3k citations). Frans Erdkamp has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Miriam Koopman, Cornelis J.A. Punt, C. J. Rodenburg, Ninja Antonini, Linda Mol, Otilia Dalesio, Harm Sinnige, Annemieke Cats, G.J. Creemers and Jolanda Schrama. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Breast Cancer Research and Treatment, International Journal of Cancer and Acta Oncologica.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact